Form 4: CG Oncology Director Sells Shares After Option Exercise

CG Oncology Director James Mulay executed a pre-planned sale of common stock following the exercise of stock options on January 9, 2026.

Summary

• James Mulay, a Director at CG Oncology, Inc. (CGON), reported transactions involving the company's common stock.
• On January 9, 2026, Mulay acquired 654 shares of common stock by exercising stock options at a price of $3.72 per share.
• Concurrently, on January 9, 2026, Mulay disposed of 654 shares of common stock at a price of $44.16 per share.
• Also on January 9, 2026, Mulay acquired an additional 10,491 shares of common stock by exercising stock options at a price of $12.59 per share.
• Immediately following this, Mulay disposed of 10,491 shares of common stock at a price of $52.99 per share.
• All sales were conducted pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025.
• The first stock option grant (654 shares) vests in 36 substantially equal monthly installments beginning on July 14, 2023, with an expiration date of June 13, 2033.
• The second stock option grant (10,491 shares) vests in 36 substantially equal monthly installments beginning on January 13, 2024, with an expiration date of December 12, 2033.
• Following these transactions, Mulay beneficially owns 0 shares of the common stock directly from these specific transactions, but still holds 1,308 and 5,240 derivative securities (stock options) respectively from the two grants.

Sentiment

Score: 5

Explanation: Neutral. The filing reports routine insider transactions (option exercise and sale) executed under a pre-arranged 10b5-1 plan, which is a common practice and does not inherently signal strong positive or negative sentiment about the company's future.

Positives

• The director exercised stock options, indicating that the stock's market price was significantly above the exercise price, suggesting value in the company's equity.
• The sales were executed at substantially higher prices ($44.16 and $52.99) compared to the option exercise prices ($3.72 and $12.59), demonstrating a profitable transaction for the insider.

Negatives

• The filing reports insider selling, which, while pre-planned, can sometimes be perceived negatively by the market, although the context of option exercise mitigates this.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This filing is a routine insider transaction report and does not provide specific insights into broader industry trends or competitive landscape. It reflects standard compensation practices for directors in publicly traded companies, particularly in the biotechnology sector where stock options are a common component of executive remuneration.

Corporate Governance

Stakeholder Impact

• Shareholders: May observe insider selling, but the pre-planned nature via a 10b5-1 plan and the context of option exercise for compensation purposes generally mitigate concerns about a negative signal from management.
• Employees: No direct impact mentioned.

Next Steps

• The remaining unexercised stock options will continue to vest according to their respective schedules (36 substantially equal monthly installments beginning July 14, 2023, and January 13, 2024).

Key Dates

Recommendation

The filing details routine insider transactions (option exercise and subsequent sale) executed under a pre-arranged 10b5-1 trading plan. While insider selling can sometimes be a concern, the pre-planned nature and the fact that it follows an option exercise for compensation purposes suggest it's not a signal of a negative outlook on the company. There is no new fundamental information about the company's operations or financial health to warrant a change in investment thesis based solely on this Form 4.

Keywords

CG Oncology, CGON, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Director Transaction, 10b5-1 Plan